The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2019 | AVANT: bevacizumab + oxaliplatin-based chemo for colon cancer
Thierry André, MD, Saint-Antoine Hospital, Paris, France, discusses the outcomes of the AVANT study (NCT00112918) assessing bevacizumab with oxaliplatin-based chemotherapy as adjuvant therapy for colon cancer, indicating that there may be no place for this combination in this setting for patients in stages 2 and 3. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
